The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Imcivree
To understand setmelanotide, you must understand what happens to children born without functional POMC. They are hungry from birth. Constantly, overwhelmingly hungry. They eat as much as they can access. They gain weight rapidly from infancy. By childhood they are severely obese. No diet, no willpower, no lifestyle intervention changes this — because the problem is not behavior. It is the absence of the satiety signal that would have told them to stop.
The melanocortin-4 receptor (MC4R) is the hypothalamic 'stop eating' signal. When activated by α-MSH (alpha-melanocyte-stimulating hormone), MC4R-expressing neurons in the arcuate nucleus of the hypothalamus send the satiety signal that reduces appetite, increases energy expenditure, and terminates feeding behavior. The chain of events that produces α-MSH: leptin (secreted by adipose tissue in proportion to fat mass) binds the leptin receptor (LEPR) on POMC neurons in the hypothalamus; the POMC gene is expressed and the POMC protein is synthesized; PCSK1 (proprotein convertase subtilisin/kexin type 1) cleaves POMC into α-MSH and other melanocortin peptides; α-MSH binds MC4R; MC4R fires. A mutation anywhere in this chain — POMC, PCSK1, or LEPR — silences the MC4R and produces the same catastrophic result: an individual who has no functional satiety signal and who will eat continuously until physically stopped.
Setmelanotide was developed by Rhythm Pharmaceuticals to bypass all three upstream defects simultaneously. It is a direct MC4R agonist — it activates the receptor without requiring leptin, LEPR, POMC gene expression, or PCSK1 processing. The broken part of the pathway is everything above the receptor. Setmelanotide jumps over the broken part and speaks directly to the receptor itself. For the handful of patients in the world with these rare mutations, this is a mechanistically perfect solution.
THE CENTRAL TENSION
Setmelanotide achieves 80% ≥10% weight loss rates in POMC-deficient patients — among the highest responder rates of any obesity pharmacotherapy in clinical development. It restores something literally absent from these patients' neurobiology: the hypothalamic satiety signal. This precision medicine story is compelling, clearly evidenced, and appropriately approved. The tension is the community: setmelanotide is being sold and used by Polaris customers and the broader peptide community for general obesity, without genetic testing, without pathway deficiency confirmation. For the vast majority of people with obesity — who have an intact MC4R pathway that is overwhelmed by caloric surplus rather than absent — the evidence for setmelanotide's efficacy is essentially zero. Using the right drug for the wrong indication is not a small error.
Both setmelanotide and Melanotan II activate MC4R. The difference is everything else they activate — and whether that selectivity is achievable in practice at clinical doses.
Feature
Setmelanotide (Imcivree)
Melanotan II (MT-II)
MC4R activity
Primary target; high selectivity
Yes — one of four receptors activated
MC1R activity
>20-fold less than MC4R (designed selectivity) but still causes 78% hyperpigmentation in trials
Strong MC1R activation — tanning is the primary community use
MC3R activity
Minimal
Significant — appetite suppression, metabolic effects
MC5R activity
Minimal
Significant — flushing, exocrine secretion
Intended receptor
MC4R (appetite/satiety)
Originally MC1R (tanning); MC4R effects are 'side effects'
Tanning / hyperpigmentation
78% develop skin hyperpigmentation in trials (MC1R off-target); lip darkening, nevi darkening
Primary intended effect; potent tanning; mole darkening
Spontaneous erections
Rare sexual AEs documented; MC4R mechanism shared with PT-141
Common; MC4R activation; this effect drove PT-141 development
Cardiovascular effects
Hypertension not observed in trials despite MC4R cardiovascular mechanism concern
HR and BP elevation documented (MC4R sympathetic activation)
FDA approval
Yes — specific genetic indications
No — not approved anywhere
Melanoma concern
Lower but present — MC1R off-target; no malignant changes in trials to date; systematic dermatological monitoring
Higher — stronger MC1R activation; 4+ melanoma case reports; causality debated
Selectivity claim
Highly selective MC4R agonist (vs MT-II) — but 78% hyperpigmentation shows 'highly selective' still means 'some MC1R'
Non-selective — MC1R+MC3R+MC4R+MC5R all activated
Under normal physiology: adipose tissue accumulates → leptin secretion increases proportionally → leptin binds LEPR on hypothalamic POMC neurons → POMC neurons activated → POMC gene transcribed and POMC protein synthesized → PCSK1 cleaves POMC into α-MSH, β-MSH, and other peptides → α-MSH binds MC4R on second-order hypothalamic neurons → MC4R activation produces: appetite suppression, increased energy expenditure, and reduction of feeding behavior. The system is a feedback loop: more fat → more leptin → more α-MSH → more MC4R activity → less eating → less fat accumulation. MC4R is the critical effector of this feedback.
In POMC deficiency (biallelic loss-of-function mutations in the POMC gene): POMC protein is not produced → PCSK1 has no substrate → no α-MSH is generated → MC4R receives no satiety signal regardless of how much adipose tissue is present. The result: profound, insatiable hyperphagia from birth; early-onset morbid obesity; normal leptin levels (the adipose tissue is producing leptin, but there is nothing downstream to respond to it in the melanocortin axis). In LEPR deficiency: leptin is produced, circulates normally, but cannot bind its receptor on POMC neurons; POMC neurons do not activate; same downstream failure. In PCSK1 deficiency: POMC is transcribed and translated, but the enzyme that cleaves it into active α-MSH is absent; POMC cannot be processed; same result. All three deficiencies lead to MC4R starvation — a receptor that should be constantly being activated by the body's own satiety signal receiving nothing.
Setmelanotide is a direct, highly selective MC4R agonist. It bypasses the entire defective upstream pathway and speaks directly to the receptor. With setmelanotide: leptin signaling, LEPR function, POMC expression, and PCSK1 processing are all irrelevant — the exogenous peptide activates MC4R directly. The receptor receives the satiety signal it has never received before. Appetite normalizes. Hyperphagia resolves. Weight loss follows, not from suppression of a normal appetite, but from restoration of an appetite regulation system that was never functioning.
Approval
Year
Indication
Age
Initial FDA approval
November 2020
Chronic weight management: POMC, PCSK1, or LEPR deficiency (genetically confirmed)
Adults and children ≥6 years
BBS expansion
2022
Bardet-Biedl syndrome (BBS) — rare ciliopathy causing obesity among multiple symptoms
Adults and children ≥2 years
VENTURE extension
2024 application
POMC/LEPR/BBS in younger patients
Ages 2-5 (VENTURE trial; Lancet Diab Endocrinol 2024)
Acquired hypothalamic obesity
March 2026
Hypothalamic obesity from damage to the hypothalamus (craniopharyngioma, brain injury, radiation) — different mechanism, same MC4R bypass approach
Adults and children ≥4 years
The genetic testing requirement: FDA approval for POMC/PCSK1/LEPR deficiency specifically requires genetically confirmed variants interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). This is a molecular medicine approach — you need a genetic test to confirm the specific indication, not just clinical obesity. This requirement is what makes off-label use without genetic testing a meaningful departure from the evidence basis.
The most compelling single data points in the setmelanotide story are from the phase II pilot study (NCT02507492): two patients with POMC deficiency received setmelanotide. Results: one patient lost 51.0 kg at week 42; the other lost 20.5 kg at week 12. Both experienced what the investigators described as 'complete reversal of hyperphagia.' Insulin resistance corrected. Quality of life dramatically improved. These are extraordinary individual outcomes that are explicable by the mechanism: patients whose satiety signal was completely absent received an exogenous version of that signal and responded proportionally. Grade A: human intervention data with clear mechanistic explanation; small n limits generalizability but the magnitude and mechanism coherence are compelling.
Clément K, van den Akker E, Argente J, et al. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes & Endocrinology. 8(12):960-970. POMC trial (n=10; 52 weeks; open-label): 80% achieved ≥10% weight loss; mean percent change in hunger score -27.1% (p=0.0005). LEPR trial (n=11; 52 weeks; open-label): 45% achieved ≥10% weight loss; mean hunger score -43.7% (p<0.0001). Safety: injection site reactions in all participants; hyperpigmentation in 78%; nausea and vomiting. No serious treatment-related adverse events. These trials, with their small numbers necessitated by the extreme rarity of these conditions, represent definitive evidence for the approved indications.
Sadaf Farooqi et al. (2024). VENTURE trial (NCT04966741); Phase 3; open-label; n=12; ages 2-5 years; POMC/LEPR deficiency and BBS; 52 weeks primary, 18-month extension. Results at 52 weeks: 83% reached clinically meaningful BMI Z-score reduction (≥0.2 points); mean -18% BMI (SD 13); -26% in the POMC/LEPR subgroup. 91% of caregivers reported patients were less hungry. 18-month data (ESPE/ESE 2025 congress): mean -23.3% BMI maintained and deepening. Safety: skin hyperpigmentation 87.5% (all treatment-related); no serious adverse events. First approved therapy for this age group.
Trial
n
Duration
Grade
Key Weight Result
Key Hunger Result
Phase II pilot (NCT02507492; POMC)
2
42-52 weeks
A
51 kg and 20.5 kg individual losses; dramatic
Complete reversal of hyperphagia in both patients
Phase 3 POMC (Clément 2020; Lancet DE)
10
52 weeks
A
80% achieved ≥10% weight loss
Hunger score -27.1% (p=0.0005)
Phase 3 LEPR (Clément 2020; Lancet DE)
11
52 weeks
A
45% achieved ≥10% weight loss
Hunger score -43.7% (p<0.0001)
VENTURE (Lancet DE 2024; ages 2-5)
12
52 weeks (18-month ext.)
A
-18% to -23.3% BMI; 83% meaningful BMI Z-score reduction
91% caregivers reported less hunger
BBS Phase 3 (Haws 2021; NEJM)
44
52 weeks
A
~10% weight loss; significant vs placebo
Significant hunger score reduction
78% of patients across trials develop skin hyperpigmentation. This is an off-target MC1R effect — despite setmelanotide's design to be selective for MC4R, it still activates MC1R on skin melanocytes at clinical doses, driving eumelanin production. Clinical manifestations: generalized skin darkening (tanning appearance); darkening of the lips and naevi (moles); occasional hair color darkening particularly in POMC-deficient patients. Important safety context: no malignant skin changes have been observed in setmelanotide clinical trials to date. Dermatological monitoring is built into the approved indication's clinical management guidelines. Any new or changing moles during setmelanotide treatment should be evaluated by a dermatologist.
SKIN MONITORING MANDATORY
Because setmelanotide activates MC1R and causes melanocyte stimulation, the same dermatological monitoring protocol that applies to Melanotan II use applies to setmelanotide. Baseline full-body dermatological exam and mole photography before starting. Any new or rapidly changing mole during treatment: dermatologist evaluation before continuing. This applies to community users accessing setmelanotide through Polaris and to prescription patients. The risk is lower magnitude than MT-II (less MC1R activity) but the mechanism and monitoring requirement are identical.
From Phase 3 trials: injection site reactions 96% (all patients; usually mild; rotate sites); skin hyperpigmentation 78%; nausea 56%; headache 41%; diarrhea 37%; vomiting 37%. These rates are high in absolute terms but must be interpreted in context: these are patients with severe, lifelong, treatment-refractory obesity for whom setmelanotide produces transformative weight loss. The adverse effect profile was acceptable to both patients and regulators given the clinical benefit in the appropriate population.
Sexual adverse events including priapism: rare; consistent with the shared MC4R mechanism that drives erections in MT-II and sexual arousal in PT-141. Priapism (erection lasting >4 hours) is a medical emergency. Community users should be aware this is a class effect of MC4R agonism at any potency level. Depression and suicidal ideation: occurred infrequently in trials and were assessed as not related to setmelanotide; however, these patients have severe chronic disease and mental health monitoring is appropriate. No clinically significant hypertension signal was observed, despite theoretical MC4R cardiovascular concerns.
Setmelanotide: subcutaneous injection once daily. Pharmacokinetics (from prescribing information): Cmax steady state approximately 37.9 ng/mL; AUCtau approximately 495 h×ng/mL; both increase proportionally with dose (linear PK). Half-life supports once-daily dosing. Dose titration schedule: prescribed dose titration over several weeks to minimize injection site reactions and GI adverse effects during initiation. The approved dose range in clinical trials was 1.5-3 mg once daily SubQ; the specific approved dose for each indication is in the prescribing information.
Injection sites: abdomen, thigh, or upper arm; rotate sites to minimize ISR accumulation at any single site. Community (Polaris) access uses the same SubQ peptide injection approach as other research peptides, with the same reconstitution and storage requirements (refrigerate; use within defined window; bacteriostatic water reconstitution).
Polaris carries setmelanotide. Community users are accessing it for general obesity without genetic testing. The evidence does not support this use — but the mechanism invites the question.
The off-label appeal is understandable: setmelanotide produces 10-26% weight loss in people who have never been able to lose weight by any other means. It restores the satiety signal. It directly activates the hypothalamic circuit that controls hunger. If it works this powerfully in pathway-deficient patients, won't it work in everyone? The pharmacological answer: probably less so, and possibly not at all for weight loss in pathway-intact individuals. In common obesity, the MC4R pathway is not absent — it is receiving its normal satiety signals. The body is gaining weight despite a functioning satiety circuit, not because that circuit is broken. Adding more MC4R agonism beyond the physiological α-MSH signal may produce appetite suppression (GLP-1 agonists' MC4R-related hunger reduction is likely partly through this mechanism), but the dramatic weight loss in deficiency patients reflects restoration of a completely absent signal, not enhancement of a present one. The dose-response in pathway-intact individuals is unknown and may be substantially flatter.
Phase II data on heterozygous pathway variants (one functional copy, one defective): 34% of heterozygous POMC/PCSK1/LEPR variant carriers achieved ≥5% weight loss at 3 months — significantly lower than biallelic (homozygous) deficiency patients. This gradient is mechanistically consistent: partial pathway impairment produces partial response. No pathway impairment (common obesity) might produce even less. No controlled trial has evaluated setmelanotide in common obesity without pathway deficiency.
THE OFF-LABEL EVIDENCE GAP
The evidence for setmelanotide is entirely in patients with genetic MC4R pathway deficiency. No published randomized controlled trial has evaluated setmelanotide in common/polygenic obesity without confirmed pathway deficiency. Community users accessing setmelanotide through Polaris without genetic testing are using a drug with compelling evidence for 0.1% of the obese population in a context for which no evidence exists. The melanoma monitoring requirement, injection site reactions (96%), skin hyperpigmentation (78%), and rare priapism apply regardless of indication.
Setmelanotide is more selective than MT-II — it activates MC4R with much less MC1R activity. But 78% of patients still develop skin hyperpigmentation in trials. The melanoma mechanism (MC1R-driven melanocyte stimulation) applies to setmelanotide at clinical doses, albeit with less intensity than MT-II. It is not accurate to describe setmelanotide as a 'safe tanning alternative' to MT-II. The dermatological monitoring requirements are the same; the concern is reduced in magnitude, not eliminated.
POMC-deficient patients are gaining weight because their MC4R receives no satiety signal. Setmelanotide provides that signal. Common obesity patients are gaining weight despite their MC4R receiving normal satiety signals — the problem is caloric excess overcoming a functioning system, not a broken system. Replacing a missing signal is mechanistically different from augmenting a present one. The clinical evidence does not support extrapolating POMC/LEPR deficiency outcomes to general obesity.
FDA approval for specific genetic indications is not approval for general obesity. The approval is based on trials in patients with confirmed genetic mutations who have severe early-onset disease. The adverse effect profile (96% ISR, 78% hyperpigmentation, 56% nausea) was acceptable in that context because of transformative weight loss benefits in a population with no alternatives. Those same adverse effects in community users seeking modest weight loss from a functioning MC4R pathway represent a different benefit-risk calculation.
Clément K, van den Akker E, Argente J, et al. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes & Endocrinology. 8(12):960-970. [The foundational Phase 3 trials; POMC n=10: 80% ≥10% weight loss; hunger -27.1%; LEPR n=11: 45% ≥10% weight loss; hunger -43.7%.]
Farooqi IS, et al. (2024). Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes & Endocrinology. [n=12; ages 2-5; mean -18% BMI at 52 weeks; -26% POMC/LEPR subgroup; 83% meaningful BMI Z-score reduction; extended to 18 months (-23.3%) at ECEESPE2025.]
Haws R, et al. (2021). Setmelanotide (RM-493), a melanocortin-4 receptor agonist, improves obesity in Bardet-Biedl syndrome and POMC deficiency: Phase 3 trials. NEJM. [BBS indication; n=44 patients; significant weight loss vs placebo crossover design; basis for BBS approval.]
Rhythm Pharmaceuticals press release (March 2026). FDA approves IMCIVREE for acquired hypothalamic obesity. [Third FDA approval expanding indication to hypothalamic obesity from craniopharyngioma, radiation, brain injury.]
Collet TH, Dubern B, Mokrosinski J, et al. (2017). Evaluation of a melanocortin-4 receptor (MC4R) agonist (setmelanotide) in MC4R deficiency. Molecular Metabolism. [MC4R deficiency patients; potential efficacy signal; ongoing expansion of indication research.]
Setmelanotide is precision medicine for a rare disease — one of the clearest examples of mechanism-matched pharmacotherapy in all of obesity medicine. For the patients it was designed for, it is transformative. For the community using it off-label without genetic testing, the evidence basis for use simply does not exist.
The drug's story resolves clearly: the POMC/LEPR/PCSK1/BBS patients who received setmelanotide in clinical trials had never been able to manage their weight by any means because their hypothalamic satiety circuit was functionally absent. Setmelanotide restored that circuit directly. The outcomes — 80% ≥10% weight loss, 51 kg individual losses, complete reversal of hyperphagia — are some of the most compelling obesity pharmacotherapy results in the literature, precisely because the mechanism is so perfectly matched to the disease. The challenge for the community: this mechanism does not extrapolate to common obesity where the circuit is intact. Skin monitoring is mandatory regardless of indication. The melanoma concern is lower than MT-II but present.
— End of Setmelanotide —
THE PEPTIDE BIBLE | Setmelanotide (Imcivree) | For Research & Educational Purposes Only
Setmelanotide (Imcivree; BIM-22493/RM-493; Rhythm Pharmaceuticals): cyclic octapeptide; Ac-Arg-c[Cys-Glu-His-D-Phe-Arg-Trp-Cys]-NH₂; MW ~1117 Da; highly selective MC4R agonist (>20-fold less MC1R activity than clinical doses but still causes 78% skin hyperpigmentation). FDA APPROVED: November 2020 (POMC/PCSK1/LEPR deficiency); 2022 (Bardet-Biedl syndrome); March 2026 (acquired hypothalamic obesity). Subcutaneous injection once daily. Polaris carries it. THE PATHWAY: Leptin → LEPR → POMC neurons → PCSK1 → α-MSH → MC4R → satiety. In POMC/LEPR/PCSK1 deficiency: chain broken upstream of MC4R → no satiety signal → constant hyperphagia from birth → severe early-onset obesity. Setmelanotide bypasses entire broken chain by directly activating MC4R. EVIDENCE: Phase II pilot (n=2 POMC; one patient -51 kg at week 42; complete hyperphagia reversal). Phase 3 POMC trial (Clément 2020 Lancet DE; n=10; 52 weeks): 80% ≥10% weight loss; hunger -27.1% (p=0.0005). Phase 3 LEPR trial (same paper; n=11): 45% ≥10% weight loss; hunger -43.7% (p<0.0001). VENTURE (Lancet DE 2024; n=12; ages 2-5): -18% to -23.3% BMI at 12-18 months; 83% meaningful BMI Z-score reduction. BBS (Haws 2021 NEJM; n=44): significant weight loss vs placebo. ADVERSE EFFECTS: injection site reactions 96% (all patients; rotate sites); skin hyperpigmentation 78% (MC1R off-target; lip/nevi darkening; hair darkening; no malignant changes observed); nausea 56%; headache 41%; diarrhea 37%; vomiting 37%; priapism rare (MC4R sexual effect). SKIN MONITORING MANDATORY: baseline dermatological exam + mole photography; evaluate any new/changing mole; same protocol as MT-II. No hypertension signal observed despite MC4R cardiovascular mechanism concern. PHARMACOKINETICS: Cmax steady state ~37.9 ng/mL; AUCtau ~495 h×ng/mL; linear PK. OFF-LABEL COMMUNITY USE: evidence is exclusively in pathway-deficiency patients (0.1% of obese population). No trial in common/polygenic obesity without pathway mutation. Heterozygous variants: only 34% achieve ≥5% weight loss (vs biallelic deficiency response). MC4R pathway intact in common obesity — restoring an absent signal vs augmenting a present one is mechanistically different. GENETIC TESTING REQUIRED for appropriate use: POMC/PCSK1/LEPR sequencing; BBS panel. vs MT-II: setmelanotide more MC4R-selective (less non-MC4R effects) but hyperpigmentation still 78%; melanoma monitoring applies to both; setmelanotide not a 'safe tanning alternative.' WADA: not listed; MC4R agonists warrant consultation for competitive athletes.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.